Employing genetic markers to improve diagnosis of thyroid tumor fine needle biopsy

Current Genomics

Volumn 12, Issue 8, 2011, Pages 589-596

  Cerutti, Janete M ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

FNA; Follicular thyroid adenoma; Follicular thyroid carcinoma; Indeterminate nodule; ITM1 and C1orf24; Molecular markers

Indexed keywords

B RAF KINASE; DNA; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; K RAS PROTEIN; MICRORNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN RET; RAS PROTEIN; RNA; TRANSCRIPTION FACTOR PAX8; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; ASPIRATION CYTOLOGY; CANCER CYTODIAGNOSIS; CANCER DIAGNOSIS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; GENE EXPRESSION PROFILING; GENE REARRANGEMENT; GENETIC MARKER; HEALTH CARE COST; HUMAN; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC THYROIDITIS; MUTATIONAL ANALYSIS; NEEDLE BIOPSY; ONCOCYTOMA; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; POINT MUTATION; PREOPERATIVE EVALUATION; SENSITIVITY AND SPECIFICITY; SOMATIC MUTATION; THYROID ADENOMA; THYROID CANCER; THYROID FOLLICULAR CARCINOMA; THYROID NODULE; THYROID PAPILLARY CARCINOMA; THYROID TUMOR; TUMOR CLASSIFICATION; TUMOR DIAGNOSIS; UNDIFFERENTIATED CARCINOMA;

EID: 82055197096     PISSN: 13892029     EISSN: 18755488     Source Type: Journal    
DOI: 10.2174/138920211798120781     Document Type: Article

References (75)

1. Mazzaferri, E. L. Management of a solitary thyroid nodule. N. Engl. J. Med., 1993, 328(8), 553-559.
2. Ezzat, S.; Sarti, D. A.; Cain, D. R.; Braunstein, G. D. Thyroid incidentalomas. Prevalence by palpation and ultrasonography. Arch. Intern. Med., 1994, 154(16), 1838-1840.
3. Tan, G. H.; Gharib, H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann. Intern. Med., 1997, 126(3), 226-231.
4. Baloch, Z. W.; Gupta, P. K.; Yu, G. H.; Sack, M. J.; LiVolsi, V. A. Follicular variant of papillary carcinoma. Cytologic and histologic correlation. Am. J. Clin. Pathol., 1999, 111(2), 216-222.
5. Baloch, Z. W.; Livolsi, V. A. Follicular-patterned lesions of the thyroid: the bane of the pathologist. Am. J. Clin. Pathol., 2002, 117(1), 143-150.
6. Logani, S.; Gupta, P. K.; LiVolsi, V. A.; Mandel, S.; Baloch, Z. W. Thyroid nodules with FNA cytology suspicious for follicular variant of papillary thyroid carcinoma: follow-up and management. Diagn. Cytopathol., 2000, 23(6), 380-385.
7. Bartolazzi, A.; Orlandi, F.; Saggiorato, E.; Volante, M.; Arecco, F.; Rossetto, R.; Palestini, N.; Ghigo, E.; Papotti, M.; Bussolati, G.; Martegani, M. P.; Pantellini, F.; Carpi, A.; Giovagnoli, M. R.; Monti, S.; Toscano, V.; Sciacchitano, S.; Pennelli, G. M.; Mian, C.; Pelizzo, M. R.; Rugge, M.; Troncone, G.; Palombini, L.; Chiappetta, G.; Botti, G.; Vecchione, A.; Bellocco, R. Galectin-3- expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol., 2008, 9(6), 543-549.
8. Yeh, M. W.; Demircan, O.; Ituarte, P.; Clark, O. H. False-negative fine-needle aspiration cytology results delay treatment and adversely affect outcome in patients with thyroid carcinoma. Thyroid, 2004, 14(3), 207-215.
9. Chow, L. S.; Gharib, H.; Goellner, J. R.; van Heerden, J. A. Nondiagnostic thyroid fine-needle aspiration cytology: management dilemmas. Thyroid, 2001, 11(12), 1147-1151.
10. Layfield, L. J.; Abrams, J.; Cochand-Priollet, B.; Evans, D.; Gharib, H.; Greenspan, F.; Henry, M.; LiVolsi, V.; Merino, M.; Michael, C. W.; Wang, H.; Wells, S. A. Post-thyroid FNA testing and treatment options: a synopsis of the National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference. Diagn. Cytopathol., 2008, 36(6), 442-448.
11. Baloch, Z. W.; Cibas, E. S.; Clark, D. P.; Layfield, L. J.; Ljung, B. M.; Pitman, M. B.; Abati, A. The National Cancer Institute Thyroid fine needle aspiration state of the science conference: a summation. Cytojournal, 2008, 5(6), 1-17.
12. Layfield, L. J.; Cibas, E. S.; Gharib, H.; Mandel, S. J. Thyroid aspiration cytology: current status. CA Cancer J. Clin., 2009, 59(2), 99-110.
13. Layfield, L. J.; Morton, M. J.; Cramer, H. M.; Hirschowitz, S. Implications of the proposed thyroid fine-needle aspiration category of follicular lesion of undetermined significance: A five-year multi-institutional analysis. Diagn. Cytopathol., 2009, 37(10), 710-714.
14. Kroll, T. G.; Sarraf, P.; Pecciarini, L.; Chen, C. J.; Mueller, E.; Spiegelman, B. M.; Fletcher, J. A. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science, 2000, 289(5483), 1357-1360.
15. Nakabashi, C. C.; Guimaraes, G. S.; Michaluart, P., Jr.; Ward, L. S.; Cerutti, J. M.; Maciel, R. M. The expression of PAX8- PPARgamma rearrangements is not specific to follicular thyroid carcinoma. Clin. Endocrinol. (Oxf), 2004, 61(2), 280-282.
16. Cheung, L.; Messina, M.; Gill, A.; Clarkson, A.; Learoyd, D.; Delbridge, L.; Wentworth, J.; Philips, J.; Clifton-Bligh, R.; Robinson, B. G. Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas. J. Clin. Endocrinol. Metab., 2003, 88(1), 354-357.
17. Freitas, B. C.; Cerutti, J. M. Genetic markers differentiating follicular thyroid carcinoma from benign lesions. Mol. Cell. Endocrinol., 2010, 321(1), 77-85.
18. Lui, W. O.; Zeng, L.; Rehrmann, V.; Deshpande, S.; Tretiakova, M.; Kaplan, E. L.; Leibiger, I.; Leibiger, B.; Enberg, U.; Hoog, A.; Larsson, C.; Kroll, T. G. CREB3L2-PPARgamma fusion mutation identifies a thyroid signaling pathway regulated by intramembrane proteolysis. Cancer Res., 2008, 68(17), 7156-7164.
19. Eberhardt, N. L.; Grebe, S. K.; McIver, B.; Reddi, H. V. The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer. Mol. Cell. Endocrinol., 2010, 321(1), 50-56.
20. Dahia, P. L.; Marsh, D. J.; Zheng, Z.; Zedenius, J.; Komminoth, P.; Frisk, T.; Wallin, G.; Parsons, R.; Longy, M.; Larsson, C.; Eng, C. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res., 1997, 57(21), 4710-4713.
21. Liu, Z.; Hou, P.; Ji, M.; Guan, H.; Studeman, K.; Jensen, K.; Vasko, V.; El-Naggar, A. K.; Xing, M. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3- kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J. Clin. Endocrinol. Metab., 2008, 93(8), 3106-3116.
22. Vasko, V.; Ferrand, M.; Di Cristofaro, J.; Carayon, P.; Henry, J. F.; de Micco, C. Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J. Clin. Endocrinol. Metab., 2003, 88(6), 2745-2752.
23. Nikiforova, M. N.; Lynch, R. A.; Biddinger, P. W.; Alexander, E. K.; Dorn, G. W., 2nd; Tallini, G.; Kroll, T. G.; Nikiforov, Y. E. RAS Point Mutations and PAX8-PPARgamma Rearrangement in Thyroid Tumors: Evidence for Distinct Molecular Pathways in Thyroid Follicular Carcinoma. J. Clin. Endocrinol. Metab., 2003, 88(5), 2318-2326.
24. Nikiforov, Y. E.; Steward, D. L.; Robinson-Smith, T. M.; Haugen, B. R.; Klopper, J. P.; Zhu, Z.; Fagin, J. A.; Falciglia, M.; Weber, K.; Nikiforova, M. N. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J. Clin. Endocrinol. Metab., 2009, 94(6), 2092-2098.
25. Kimura, E. T.; Nikiforova, M. N.; Zhu, Z.; Knauf, J. A.; Nikiforov, Y. E.; Fagin, J. A. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res., 2003, 63(7), 1454-1457.
26. Rowe, L. R.; Bentz, B. G.; Bentz, J. S. Detection of BRAF V600E activating mutation in papillary thyroid carcinoma using PCR with allele-specific fluorescent probe melting curve analysis. J. Clin. Pathol., 2007, 60(11), 1211-1215.
27. Sapio, M. R.; Posca, D.; Raggioli, A.; Guerra, A.; Marotta, V.; Deandrea, M.; Motta, M.; Limone, P. P.; Troncone, G.; Caleo, A.; Rossi, G.; Fenzi, G.; Vitale, M. Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings. Clin. Endocrinol. (Oxf), 2007, 66(5), 678-683.
28. Xing, M.; Clark, D.; Guan, H.; Ji, M.; Dackiw, A.; Carson, K. A.; Kim, M.; Tufaro, A.; Ladenson, P.; Zeiger, M.; Tufano, R. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J. Clin. Oncol., 2009, 27(18), 2977-2982.
29. Adeniran, A. J.; Theoharis, C.; Hui, P.; Prasad, M. L.; Hammers, L.; Carling, T.; Udelsman, R.; Chhieng, D. C. Reflex BRAF Testing in Thyroid Fine-Needle Aspiration Biopsy with Equivocal and Positive Interpretation: A Prospective Study. Thyroid, 2011, 21(7), 717-723.
30. Cohen, Y.; Rosenbaum, E.; Clark, D. P.; Zeiger, M. A.; Umbricht, C. B.; Tufano, R. P.; Sidransky, D.; Westra, W. H. Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin. Cancer Res., 2004, 10(8), 2761-2765.
31. Kang, G.; Cho, E. Y.; Shin, J. H.; Chung, J. H.; Kim, J. W.; Oh, Y. L. Role of BRAFV600E mutation analysis and second cytologic review of fine-needle aspiration for evaluating thyroid nodule. Cancer Cytopathol., 2011 [Epub ahead of print].
32. Cantara, S.; Capezzone, M.; Marchisotta, S.; Capuano, S.; Busonero, G.; Toti, P.; Di Santo, A.; Caruso, G.; Carli, A. F.; Brilli, L.; Montanaro, A.; Pacini, F. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J. Clin. Endocrinol. Metab., 2010, 95(3), 1365-1369.
33. Moses, W.; Weng, J.; Sansano, I.; Peng, M.; Khanafshar, E.; Ljung, B. M.; Duh, Q. Y.; Clark, O. H.; Kebebew, E. Molecular testing for somatic mutations improves the accuracy of thyroid fine-needle aspiration biopsy. World J. Surg., 2010, 34(11), 2589-2594.
34. Ohori, N. P.; Nikiforova, M. N.; Schoedel, K. E.; LeBeau, S. O.; Hodak, S. P.; Seethala, R. R.; Carty, S. E.; Ogilvie, J. B.; Yip, L.; Nikiforov, Y. E. Contribution of molecular testing to thyroid fineneedle aspiration cytology of follicular lesion of undetermined significance/atypia of undetermined significance. Cancer Cytopathol., 2010, 118(1), 17-23.
35. Oler, G.; Cerutti, J. M. High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes. Cancer, 2009, 115(5), 972-980.
36. Xing, M. Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol. Cell. Endocrinol., 321(1), 86-93.
37. Elisei, R.; Ugolini, C.; Viola, D.; Lupi, C.; Biagini, A.; Giannini, R.; Romei, C.; Miccoli, P.; Pinchera, A.; Basolo, F. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J. Clin. Endocrinol. Metab., 2008, 93(10), 3943-3949.
38. Oler, G.; Ebina, K. N.; Michaluart, P., Jr.; Kimura, E. T.; Cerutti, J. Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis reveals a new mutation in metastasis. Clin. Endocrinol. (Oxf), 2005, 62(4), 509-511.
39. Basolo, F.; Torregrossa, L.; Giannini, R.; Miccoli, M.; Lupi, C.; Sensi, E.; Berti, P.; Elisei, R.; Vitti, P.; Baggiani, A.; Miccoli, P. Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J. Clin. Endocrinol. Metab., 2010, 95(9), 4197-4205.
40. Durante, C.; Puxeddu, E.; Ferretti, E.; Morisi, R.; Moretti, S.; Bruno, R.; Barbi, F.; Avenia, N.; Scipioni, A.; Verrienti, A.; Tosi, E.; Cavaliere, A.; Gulino, A.; Filetti, S.; Russo, D. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J. Clin. Endocrinol. Metab., 2007, 92(7), 2840-2843.
41. Melillo, R. M.; Castellone, M. D.; Guarino, V.; De Falco, V.; Cirafici, A. M.; Salvatore, G.; Caiazzo, F.; Basolo, F.; Giannini, R.; Kruhoffer, M.; Orntoft, T.; Fusco, A.; Santoro, M. The RET/PTCRAS- BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J. Clin. Invest., 2005, 115(4), 1068-1081.
42. Romei, C.; Ciampi, R.; Faviana, P.; Agate, L.; Molinaro, E.; Bottici, V.; Basolo, F.; Miccoli, P.; Pacini, F.; Pinchera, A.; Elisei, R. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocr. Relat. Cancer, 2008, 15(2), 511-520.
43. Orlandi, F.; Saggiorato, E.; Pivano, G.; Puligheddu, B.; Termine, A.; Cappia, S.; De Giuli, P.; Angeli, A. Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res., 1998, 58(14), 3015-3020.
44. Xu, X. C.; el-Naggar, A. K.; Lotan, R. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am. J. Pathol., 1995, 147(3), 815-822.
45. Prasad, M. L.; Pellegata, N. S.; Huang, Y.; Nagaraja, H. N.; Chapelle Ade, L.; Kloos, R. T. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod. Pathol., 2005, 18(1), 48-57.
46. Barroeta, J. E.; Baloch, Z. W.; Lal, P.; Pasha, T. L.; Zhang, P. J.; LiVolsi, V. A. Diagnostic value of differential expression of CK19, Galectin-3, HBME-1, ERK, RET, and p16 in benign and malignant follicular-derived lesions of the thyroid: an immunohistochemical tissue microarray analysis. Endocr. Pathol., 2006, 17(3), 225-234.
47. Saggiorato, E.; De Pompa, R.; Volante, M.; Cappia, S.; Arecco, F.; Dei Tos, A. P.; Orlandi, F.; Papotti, M. Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr. Relat. Cancer, 2005, 12(2), 305-317.
48. de Matos, P. S.; Ferreira, A. P.; de Oliveira Facuri, F.; Assumpcao, L. V.; Metze, K.; Ward, L. S. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology, 2005, 47(4), 391-401.
49. Barden, C. B.; Shister, K. W.; Zhu, B.; Guiter, G.; Greenblatt, D. Y.; Zeiger, M. A.; Fahey, T. J., 3rd. Classification of follicular thyroid tumors by molecular signature: results of gene profiling. Clin. Cancer Res., 2003, 9(5), 1792-1800.
50. Weber, F.; Shen, L.; Aldred, M. A.; Morrison, C. D.; Frilling, A.; Saji, M.; Schuppert, F.; Broelsch, C. E.; Ringel, M. D.; Eng, C. Genetic classification of benign and malignant thyroid follicular neoplasia based on a three-gene combination. J. Clin. Endocrinol. Metab., 2005, 90(5), 2512-2521.
51. Takano, T.; Yamada, H. Trefoil factor 3 (TFF3): a promising indicator for diagnosing thyroid follicular carcinoma. Endocr. J., 2009, 56(1), 9-16.
52. Patel, M. R.; Bryson, P. C.; Shores, C. G.; Hart, C. F.; Thorne, L. B.; Deal, A. M.; Zanation, A. M. Trefoil factor 3 immunohistochemical characterization of follicular thyroid lesions from tissue microarray. Arch. Otolaryngol. Head Neck Surg., 2009, 135(6), 590-596.
53. Foukakis, T.; Gusnanto, A.; Au, A. Y.; Hoog, A.; Lui, W. O.; Larsson, C.; Wallin, G.; Zedenius, J. A PCR-based expression signature of malignancy in follicular thyroid tumors. Endocr. Relat. Cancer, 2007, 14(2), 381-391.
54. Krause, K.; Eszlinger, M.; Gimm, O.; Karger, S.; Engelhardt, C.; Dralle, H.; Fuhrer, D. TFF3-based candidate gene discrimination of benign and malignant thyroid tumors in a region with borderline iodine deficiency. J. Clin. Endocrinol. Metab., 2008, 93(4), 1390-1393.
55. Boon, K.; Osorio, E. C.; Greenhut, S. F.; Schaefer, C. F.; Shoemaker, J.; Polyak, K.; Morin, P. J.; Buetow, K. H.; Strausberg, R. L.; De Souza, S. J.; Riggins, G. J. An anatomy of normal and malignant gene expression. Proc. Natl. Acad. Sci. USA, 2002, 99(17), 11287-11292.
56. Cerutti, J. M.; Delcelo, R.; Amadei, M. J.; Nakabashi, C.; Maciel, R. M.; Peterson, B.; Shoemaker, J.; Riggins, G. J. A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression. J. Clin. Invest., 2004, 113(8), 1234-1242.
57. Cerutti, J. M.; Latini, F. R.; Nakabashi, C.; Delcelo, R.; Andrade, V. P.; Amadei, M. J.; Maciel, R. M.; Hojaij, F. C.; Hollis, D.; Shoemaker, J.; Riggins, G. J. Diagnosis of suspicious thyroid nodules using four protein biomarkers. Clin. Cancer Res., 2006, 12(11 Pt 1), 3311-3318.
58. Cerutti, J. M.; Oler, G.; Delcelo, R.; Gerardt, R.; Michaluart, P., Jr.; de Souza, S. J.; Galante, P. A.; Huang, P.; Riggins, G. J. PVALB, a new Hurthle adenoma diagnostic marker identified through gene expression. J. Clin. Endocrinol. Metab., 2011, 96(1), E151-60.
59. Matsumoto, F.; Fujii, H.; Abe, M.; Kajino, K.; Kobayashi, T.; Matsumoto, T.; Ikeda, K.; Hino, O. A novel tumor marker, Niban, is expressed in subsets of thyroid tumors and Hashimoto's thyroiditis. Hum. Pathol., 2006, 37(12), 1592-1600.
60. Bryson, P. C.; Shores, C. G.; Hart, C.; Thorne, L.; Patel, M. R.; Richey, L.; Farag, A.; Zanation, A. M. Immunohistochemical distinction of follicular thyroid adenomas and follicular carcinomas. Arch. Otolaryngol. Head Neck Surg., 2008, 134(6), 581-586.
61. Patel, M. R.; Stadler, M. E.; Deal, A. M.; Kim, H. S.; Shores, C. G.; Zanation, A. M. STT3A, C1orf24, TFF3: putative markers for characterization of follicular thyroid neoplasms from fine-needle aspirates. Laryngoscope, 2011 121(5), 983-989.
62. Majima, S.; Kajino, K.; Fukuda, T.; Otsuka, F.; Hino, O. A novel gene Niban upregulated in renal carcinogenesis: cloning by the cDNA-amplified fragment length polymorphism approach. Jpn. J. Cancer Res., 2000, 91(9), 869-874.
63. Garcia-Rostan, G.; Costa, A. M.; Pereira-Castro, I.; Salvatore, G.; Hernandez, R.; Hermsem, M. J.; Herrero, A.; Fusco, A.; Cameselle-Teijeiro, J.; Santoro, M. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res., 2005, 65(22), 10199-10207.
64. Halachmi, N.; Halachmi, S.; Evron, E.; Cairns, P.; Okami, K.; Saji, M.; Westra, W. H.; Zeiger, M. A.; Jen, J.; Sidransky, D. Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors. Genes Chromosomes Cancer, 1998, 23(3), 239-243.
65. Wu, G.; Mambo, E.; Guo, Z.; Hu, S.; Huang, X.; Gollin, S. M.; Trink, B.; Ladenson, P. W.; Sidransky, D.; Xing, M. Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J. Clin. Endocrinol. Metab., 2005, 90(8), 4688-4693.
66. Ricarte-Filho, J. C.; Ryder, M.; Chitale, D. A.; Rivera, M.; Heguy, A.; Ladanyi, M.; Janakiraman, M.; Solit, D.; Knauf, J. A.; Tuttle, R. M.; Ghossein, R. A.; Fagin, J. A. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res., 2009, 69(11), 4885-4893.
67. Hemerly, J. P.; Bastos, A. U.; Cerutti, J. M. Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas. Eur. J. Endocrinol., 2010, 163(5), 747-755.
68. Murugan, A. K.; Bojdani, E.; Xing, M. Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochem. Biophys. Res. Commun., 2010, 393(3), 555-559.
69. Weber, F.; Teresi, R. E.; Broelsch, C. E.; Frilling, A.; Eng, C. A limited set of human MicroRNA is deregulated in follicular thyroid carcinoma. J. Clin. Endocrinol. Metab., 2006, 91(9), 3584-3591.
70. Nikiforova, M. N.; Tseng, G. C.; Steward, D.; Diorio, D.; Nikiforov, Y. E. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J. Clin. Endocrinol. Metab., 2008, 93(5), 1600-1608.
71. Pallante, P.; Visone, R.; Ferracin, M.; Ferraro, A.; Berlingieri, M. T.; Troncone, G.; Chiappetta, G.; Liu, C. G.; Santoro, M.; Negrini, M.; Croce, C. M.; Fusco, A. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr. Relat. Cancer, 2006, 13(2), 497-508.
72. Visone, R.; Pallante, P.; Vecchione, A.; Cirombella, R.; Ferracin, M.; Ferraro, A.; Volinia, S.; Coluzzi, S.; Leone, V.; Borbone, E.; Liu, C. G.; Petrocca, F.; Troncone, G.; Calin, G. A.; Scarpa, A.; Colato, C.; Tallini, G.; Santoro, M.; Croce, C. M.; Fusco, A. Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene, 2007, 26(54), 7590-7595.
73. Visone, R.; Russo, L.; Pallante, P.; De Martino, I.; Ferraro, A.; Leone, V.; Borbone, E.; Petrocca, F.; Alder, H.; Croce, C. M.; Fusco, A. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr. Relat. Cancer, 2007, 14(3), 791-798.
74. He, H.; Jazdzewski, K.; Li, W.; Liyanarachchi, S.; Nagy, R.; Volinia, S.; Calin, G. A.; Liu, C. G.; Franssila, K.; Suster, S.; Kloos, R. T.; Croce, C. M.; de la Chapelle, A. The role of microRNA genes in papillary thyroid carcinoma. Proc. Natl. Acad. Sci. U S A, 2005, 102(52), 19075-19080.
75. Ferraz, C.; Eszlinger, M.; Paschke, R. Current state and future perspective of molecular diagnosis of fine-needle aspiration biopsy of thyroid nodules. J. Clin. Endocrinol. Metab., 2011, 96(7), 2016-2026.